BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + Topotecan
Phase 2Active 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Extensive-stage Small-cell Lung Cancer
Conditions
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Trial Timeline
Aug 5, 2024 → May 1, 2028
NCT ID
NCT06449209About BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + Topotecan
BNT327 Dose Level 1 (DL1) + BNT327 Dose Level 2 (DL2) + Etoposide + Carboplatin + Paclitaxel + Topotecan is a phase 2 stage product being developed by BioNTech for Extensive-stage Small-cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06449209. Target conditions include Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06449209 | Phase 2 | Active |
Competing Products
20 competing products in Extensive-stage Small-cell Lung Cancer